Block listing six monthly return

RNS Number : 0081O
Polarean Imaging PLC
27 January 2023
 

 

Polarean Imaging Plc

("Polarean" or the "Company")

 

Block Listing Six Monthly Return

 

Polarean Imaging plc (AIM: POLX), the medical‑imaging technology company today makes the following notification pursuant to Schedule Six of the AIM Rules for Companies regarding its existing block admission arrangements:

 

Name of applicant:

Polarean Imaging Plc

Name of scheme:

Polarean Share Option Plan

Number and class of securities originally admitted:

8,000,000 ordinary shares of £0.00037 each

Date of admission:

29 July 2021

Period of return:

From:

28 July 2022

To:

26 January 2023

Balance of unallotted securities under scheme(s) from previous return:

4,025,657

Plus:   The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):

0

 

Less:   Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):

0

 

Equals:   Balance under scheme(s) not yet issued/allotted at end of period:

4,025,657

Total number of securities in issue at the end of the period

213,047,509






 

Name of contact:

Richard Hullihen, Chief Executive Officer

Telephone number of contact:

+  44 (0)20 7933 8780 or polarean@walbrookpr.com

 

 

 

 

Enquiries:

 

Polarean Imaging plc

www.polarean.com / www.polarean-ir.com

Richard Hullihen, Chief Executive Officer

Via Walbrook PR

Kenneth West, Chairman

 


 

Stifel Nicolaus Europe Limited (NOMAD and Sole Corporate Broker)

+44 (0)20 7710 7600

Nicholas Moore / Samira Essebiyea / Kate Hanshaw (Healthcare Investment Banking)


Nick Adams / Nick Harland (Corporate Broking)



Walbrook PR

Tel: +44 (0)20 7933 8780 or polarean@walbrookpr.com

Anna Dunphy /Phillip Marriage

Mob: +44 (0)7876 741 001 / +44 (0) 7867 984 082

 

About Polarean ( www.polarean.com )

 

The Company and its wholly owned subsidiary, Polarean, Inc. (together the "Group") are revenue-generating, medical imaging technology companies operating in the high-resolution medical imaging space. Polarean aspires to revolutionize pulmonary medicine by bringing the power and safety of MRI to the respiratory healthcare community in need of new solutions to evaluate lung function, diagnose disease, characterize disease progression, and monitor response to treatment. By researching, developing, and commercializing novel imaging solutions with a non-invasive and radiation-free functional imaging platform, Polarean's vision is to help address the global unmet medical needs of more than 500 million patients worldwide suffering with chronic respiratory disease. Polarean is a leader in the field of hyperpolarization science and has successfully developed the first and only hyperpolarized MRI contrast agent to be approved in the United States. On December 23, 2022, the FDA granted approval for Polarean's first drug device combination product, XENOVIEWTM (xenon Xe 129 hyperpolarized). 129Xe MRI is also currently being studied for visualization and quantification of gas exchange regionally in the smallest airways of the lungs, across the alveolar tissue membrane, and into the pulmonary bloodstream for future clinical indications.

 

XENOVIEWTM is a trademark of Polarean, Inc.   POL-PR-2201

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BLRNKABQNBKDFDB
UK 100

Latest directors dealings